CTLA-4 Small Molecule Degradation via LRBA Interaction Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CTLA-4 inhibitors, such as antibody drugs, face limitations including serious side effects, difficulty in intratumoral diffusion, and poor patient compliance due to their macromolecular nature, while there is a lack of CTLA-4 small molecule degradation agents that could offer improved therapeutic efficacy and safety.
Innovation Solution
Development of novel small molecule compounds with high degradation activity against CTLA-4, designed to inhibit the interaction between LRBA and CTLA-4 protein, potentially offering reduced side effects, enhanced intratumoral penetration, and improved compliance through oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CTLA-4 antibody drugs are used for immunotherapy, then anti-tumor immune response is activated, but serious side effects occur due to ADCC effect and immunogenicity
Solution Approach 1:
The patent changes the molecular size parameter from macromolecular antibodies to small molecules, fundamentally altering the drug's physical and biological properties. This parameter change eliminates ADCC effects and reduces immunogenicity while maintaining CTLA-4 inhibition capability, thereby resolving the contradiction between therapeutic efficacy and side effects
Solution Approach 2:
The patent replaces the biological mechanism of antibody-antigen interaction with a small molecule degradation mechanism. Instead of using antibodies that trigger ADCC and immune responses, the invention employs small molecules that directly degrade CTLA-4 protein through chemical bonding, substituting the biological system with a chemical system that avoids immunogenicity
2Reliability
If CTLA-4 antibody drugs are administered, then immune checkpoint inhibition is achieved, but intratumoral diffusion is difficult due to macromolecular size
Solution Approach 1:
The patent changes the size parameter of the drug molecule from macromolecular (antibody) to small molecular scale. This parameter change enables the drug to penetrate solid tumors effectively by diffusion, overcoming the size-related barrier to intratumoral delivery while maintaining the ability to inhibit CTLA-4
3Reliability
If CTLA-4 antibody drugs are used for treatment, then immune response modulation is achieved, but patient compliance is poor due to injection requirements
Solution Approach 1:
The patent changes the administration route parameter from parenteral (injection) to oral administration. This parameter change is enabled by the small molecular size and chemical stability of the compound, allowing patients to take the drug orally like conventional medications, thereby significantly improving compliance while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule compounds demonstrate strong degradation activity against CTLA-4, achieving nanomolar activity in vitro and showing excellent anti-tumor effects in tumor transplantation models, addressing the limitations of existing CTLA-4 inhibitors.
Implementation Method 1
inhibit the interaction between LRBA and CTLA-4 protein
Data Source
AI summary
A CTLA-4 small molecule degradation agent and an application thereof. The CTLA-4 small molecule degradation agent comprises a compound having the structure represented by formula I or a pharmaceutically acceptable salt, an ester, a deuterated product, an isomer, a solvate, a prodrug, or an isotopic label thereof:a new class of small molecule compounds having high degradation activity on CTLA-4. The compounds show a good degradation activity on CTLA-4 at the nanomolar (nM) level in in vitro studies.